[Improvement of bone marrow hematopoiesis in idiopathic myelofibrosis with prednisolone].
A 64 year-old female patient of idiopathic myelofibrosis (IMF), who had had rapidly progressing massive splenomegaly and severe pancytopenia refractory to blood transfusion, was treated with PSL 0.6 mg/kg/day for a month, being significantly improved not only symptomatically and hematologically but also in bone marrow hematopoiesis. Although the effectiveness of PSL to restoration of bone marrow hematopoiesis has been almost unknown, long term oral PSL should be tried for a certain phase of IMF.
Tanosaki
R
R
Department of Internal Medicine, School of Medicine, Keio University.
Uchida
H
H
Masuda
Y
Y
Michikawa
N
N
Ogawa
T
T
Kubo
A
A
Ikeda
Y
Y
D001853:Bone Marrow / Q000187:drug effects* / Q000503:physiopathology; D005260:Female; D006410:Hematopoiesis / Q000187:drug effects*; D006801:Humans; D008875:Middle Aged; D011239:Prednisolone / Q000627:therapeutic use*; D055728:Primary Myelofibrosis / Q000097:blood / Q000188:drug therapy*
D011239:Prednisolone